MOSCOW (MRC) -- Evonik Industries has
started basic engineering for the construction of a second world-scale
production plant for the amino acid DL-methionine in Singapore, said the company
on its site.
The plant complex, with a projected annual production
capacity of 150,000 metric tons, is expected to come on stream in 2019. The
Evonik committees have now approved the basic engineering.
complex will be erected next to Evonik’s existing methionine plant on Jurong
Island, Singapore, which was commissioned in late 2014. "Like our first
methionine plant in Singapore, which went on stream on schedule, this project
too is progressing according to plan," explains Reiner Beste, chairman of the
Board of the Management of Evonik Nutrition & Care GmbH.
was once again selected as the site because Evonik can service the Asian growth
market particularly well from there. And once again, in the new, fully
backward-integrated production complex, Evonik will produce all strategically
important precursors itself. "This guarantees high product quality as well as
supply security," says Beste.
The specialty chemicals group is already
producing DL-methionine at world-scale plants in Antwerp (Belgium),
Wesseling/Cologne (Germany), Mobile (Alabama, USA), and Singapore.
informed earlier, Evonik Industries acquired the
company MedPalett AS, with headquarters in Sandnes (Norway), on March 3,
2016. MedPalett AS specializes in food ingredients containing
Evonik, the creative industrial group from Germany, is one
of the world leaders in specialty chemicals. Its activities focus on the key
megatrends health, nutrition, resource efficiency and globalization. Evonik
benefits specifically from its innovative prowess and integrated technology
platforms. Evonik is active in over 100 countries around the world.